
Early-stage B2B venture capital firm backed by experienced enterprise operators who invest alongside it

Private investment company funding life science and healthcare businesses

Patient capital for life science companies comes from a New York private investment firm started in 2006 by a physician, who still leads it. Ridgeback Capital makes long-term investments in private and public companies developing therapies that save lives or change them. It says that healthcare advances take many years to arrive, which is why it values patient capital for new technologies and companies.
The firm's central idea is that long-term capital gives innovators the time they need. Its founder has provided funding to more than one hundred public and private biopharma companies over more than twenty years, with the aim of advancing medicines that address unmet needs. The firm describes its work as an investment in people as well as in science.
The site describes Ridgeback as an actively managed private investment company. It makes long-term private investments in life sciences alongside a securities trading platform, and it keeps the two strands separate. The firm says its long-term capital allows it to back innovators and help fund important change.
The founder is a licensed physician who trained in medicine in New York and holds an undergraduate degree in economics from Yale. He has been a clinical professor and a trustee at medical schools and universities, and he co-founded Ridgeback Biotherapeutics. He also co-chairs a joint steering committee with Merck for the antiviral medicine molnupiravir.
The firm's philosophy is to back ideas, technologies and companies that will make a real difference, on the view that behind every great advance is a team of people who made it happen. Its site presents the firm as makers of change and investors in humanity, and it describes the firm's long-term view of its holdings.
Ridgeback Capital is a private investment company focused on life science companies. Wayne Holman, MD, started it in 2006, and it makes long-term investments in both private and public businesses developing life-saving and life-changing therapies.
Biopharma and healthcare companies developing new medicines for unmet needs. Its founder has funded over 100 such companies over more than 20 years.
Summary written by TrustList from the business's own published information, Nov 2026.
2 images - click to enlarge
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about Ridgeback Capital.
Similar listings buyers compare against this one.

Early-stage B2B venture capital firm backed by experienced enterprise operators who invest alongside it

Startup accelerator and early-stage investor running intensive batches for new technology founders

Venture capital firm backing pre-seed deep technology startups in health and planetary sustainability

Global venture capital firm and accelerator backing early-stage technology founders, formerly called 500 Startups

Decentralised bandwidth network on which developers build and users run censorship-resistant VPN applications

A fintech-focused venture capital firm partnering with entrepreneurs across global markets

Venture capital firm funding seed and early-stage information technology and life sciences companies

Private markets asset manager investing in energy, power and infrastructure businesses worldwide
Everything here links back to the same verified catalogue. Pick your next stop.